Publications

Add filters (0)

217 results

Viewing results for fatty liver

A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

February 16, 2026

J Gastroenterol Hepatol

Abstract BACKGROUND Noninvasive fibrosis testing is crucial for metabolic dysfunction-associated steatotic liver disease (MASLD) management. This study evaluated a marker of activated mesenchymal fibrogenic cells, circulating fibroblast activation protein (cFAP), in a novel diagnostic algorithm, FAP Index, for patients with MASLD. METHODS Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n = 160) […]

Read publication

Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver Disease.

December 22, 2025

Gastroenterology

Abstract BACKGROUND & AIMS Alcohol is a key driver of liver-related mortality, and phosphatidylethanol (PEth) is a direct biomarker of alcohol intake. We investigated the prognostic performance of PEth with noninvasive liver fibrosis tests (NITs) for predicting hepatic decompensation in an alcohol-related liver disease (ALD) at-risk population. METHODS Prospective cohort study with 411 at risk […]

Read publication

Extracellular Matrix Deposition Drives Disease Progression and Reduces Rapamycin Response in LAM.

December 11, 2025

Eur Respir J

Abstract RATIONALE LAM is a rare cystic lung disease driven by nodules containing “LAM cells” and recruited LAM associated fibroblasts. Although rapamycin reduces lung function loss, some patients continue to decline, meaning additional therapies are needed. OBJECTIVES To investigate how the LAM nodule environment affects LAM cell proliferation and the response to rapamycin. METHODS Proteins […]

Read publication

Molecular signatures discriminating different types of rejection in human liver transplants.

December 1, 2025

J Hepatol

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Read publication

BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target.

November 19, 2025

Sci Rep

Abstract Fibroblast-driven deposition of extracellular matrix, particularly type III collagen, is linked to poor outcomes in patients with liver fibrosis, fibrotic solid tumors such as hepatocellular carcinoma and pancreatic cancer as well as in patients with other fibrotic diseases. The pro-peptide of type III collagen (PRO-C3) serves as a serum biomarker of active collagen formation. […]

Read publication

Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts.

November 14, 2025

Thorax

Abstract BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterised by damage to the epithelial layer, closely associated with the alveolar basement membrane (BM). We aimed to investigate how type IV collagen (COL4) in the BM changes with the progression of IPF. METHODS COL4 synthesis (PRO-C4) was detected in blood by the nordicPRO-C4 biomarker in patients with […]

Read publication

MetALD: Diagnosis and Prognosis With Non-Invasive Tests.

November 1, 2025

Aliment Pharmacol Ther

Abstract BACKGROUND Non-invasive tests (NITs) are central to diagnosing and stratifying risk in steatotic liver disease (SLD). However, it remains unclear whether guideline-recommended NIT cut-offs apply to metabolic and alcohol-related liver disease (MetALD). AIM Evaluate the diagnostic and prognostic performance of five NITs in patients with MetALD. METHODS Single-centre study with 423 SLD patients, of […]

Read publication

Serum markers of fibroinflammatory activity PRO-C3 and CPa9-HNE are associated with liver-related outcomes in patients with Chronic Hepatitis C.

October 31, 2025

J Infect Dis

Abstract BACKGROUND Chronic hepatitis C (CHC) infection remains a global health burden, contributing to the risk of long-term complications such as progressive fibrosis, cirrhosis, and hepatocellular carcinoma, particularly in undiagnosed or untreated individuals. Novel biomarkers for the assessment of disease progression and prognosis are required for fibroinflammatory chronic liver disease. Our study population from the […]

Read publication

Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis.

September 29, 2025

Chest

Abstract BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterized by an increase in proteolytic enzymes, including matrix metalloproteinases that degrade the extracellular matrix and markers of localized inflammation. Protein fragments (neoepitopes) are detectable in the circulation. RESEARCH QUESTION Can short-term trajectories of neoepitopes after initiation of antifibrotic treatment predict therapy-related outcomes, including mortality, in patients with […]

Read publication

Multi-omic spatial profiling reveals the unique SARS-CoV-2 lung microenvironment and collagen VI as a predictive biomarker in severe COVID-19.

September 1, 2025

Eur Respir J

Abstract BACKGROUND While coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, few studies have characterised the immune response to COVID-19 in lung tissue. We sought to understand the pathogenic role of microenvironmental interactions and the extracellular matrix in post-mortem COVID-19 lung using an integrative multi-omic approach. METHODS Post-mortem formalin-fixed paraffin-embedded lung tissue from fatal […]

Read publication